Drug Trial Radar · NCT00852540
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
Last checked: Nov 20, 2026Latest source record: Mar 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
410
Actual
Start
Apr 2009
Primary completion
Jul 2010
Study completion Sep 2010
Sponsor
- Lead sponsor
- Stiefel, a GSK CompanyIndustry
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline
- First posted
- Feb 27, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to provide further evidence of the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with SITL or impetigo due to MRSA. Subjects aged 2 months and older will be treated with either topical retapamulin for 5 days or oral linezolid for 10 days. The primary endpoint is the clinical response at follow-up (7-9 days after the end of therapy) in subjects who have a MRSA infection at baseline. The primary population is the per-protocol MRSA population. It is anticipated that approximately 500 subjects may be enrolled in order to obtain approximately 105 subjects who have a baseline MRSA infection.
Conditions
- Skin Infections, Bacterial
Interventions
Retpamulin Ointment, 1%Drug
Topical retapamulin (SB-275833) ointment, 1% (w/w), and placebo ointment, will be provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse-taper puncture-tip caps. Retapamulin or placebo ointment will be applied twice daily for 5 days.
LinezolidDrug
Adult and adolescent (=\>12 years of age) subjects will receive one 600mg linezolid tablet (overencapsulated), or one placebo capsule, twice daily for 10 days. Pediatric subjects aged 5-11 years will receive 10mg/kg body weight of a 100mg/5mL oral linezolid suspension, or placebo suspension, twice daily for 10 days. Pediatric subjects \<5 years of age will receive 10mg/kg of a 100mg/5mL oral linezolid suspension, or placebo suspension, three times daily for 10 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Achieving Clinical Response at Follow-up Who Had Methicillin-resistant Staphlococcus Aureus (MRSA) as a Baseline PathogenTime frame: 7-9 days post-therapy; Day 12-14 for retapamulin and Day 17-19 for linezolid
Locations
53 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Anniston, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Bentonville, Arkansas
GSK Investigational Site
Jonesboro, Arkansas
GSK Investigational Site
Paragould, Arkansas
GSK Investigational Site
Bakerfield, California
GSK Investigational Site
Bell Gardens, California
GSK Investigational Site
Huntington Beach, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Roseville, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Atlantis, Florida
GSK Investigational Site
Bay Pines, Florida
GSK Investigational Site
Fort Lauderdale, Florida
GSK Investigational Site
Fort Lauderdale, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Pensacola, Florida
GSK Investigational Site
St. Petersburg, Florida
GSK Investigational Site
Vero Beach, Florida
GSK Investigational Site
West Palm Beach, Florida
GSK Investigational Site
Columbus, Georgia
GSK Investigational Site
Macon, Georgia
GSK Investigational Site
Savannah, Georgia
GSK Investigational Site
Honolulu, Hawaii
GSK Investigational Site
Honolulu, Hawaii
GSK Investigational Site
South Bend, Indiana
GSK Investigational Site
Overland Park, Kansas
GSK Investigational Site
Louisville, Kentucky
GSK Investigational Site
New Orleans, Louisiana
GSK Investigational Site
Grand Blanc, Michigan
GSK Investigational Site
Jackson, Mississippi
GSK Investigational Site
Butte, Montana
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
Brooklyn, New York
GSK Investigational Site
Carlisle, Ohio
GSK Investigational Site
Tulsa, Oklahoma
GSK Investigational Site
Corvallis, Oregon
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.